RSP - On RAS drugs

Aus coViki
Wechseln zu: Navigation, Suche

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

plus neprilysin inhib.

  • GET ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients Extract
  • GET ä. Sacubitril/valsartan in COVID-19 patients: the need for trials Extract
GET 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. Extract


aliskiren

  • GET 2020. Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)? Extract
  • GET 2020. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension Extract

beta arrestin

  • GET 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19. Extract

AT(1-7), mas

  • GET 2020. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19 Extract
  • GET 2020. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection? Extract


other papers

  • GET 2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Extract
  • GET 2020. Two hits to the renin-angiotensin system may play a key role in severe COVID-19. Extract
GET ä. Speculation is not evidence: antihypertensive therapy and COVID-19 Extract
GET 2020. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19 Extract
  • GET ä. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis Extract
  • GET ä. Debate on Drugs That May Aggravate COVID-19 Extract
  • GET ä. Anti-RAS drugs and SARS-CoV-2 infection Extract
  • GET ä. Renin-angiotensin-aldosterone system and COVID-19 infection Extract
  • GET 2020. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19 Extract
  • GET ä. Hypertension, the renin?angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence Extract
  • GET ä. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System?a Call for Epidemiologic Investigations Extract
  • GET ä. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19 Extract
  • GET 2020. Renin-angiotensin-aldosterone system inhibitors and COVID-19 Extract
  • GET 2020. COVID-19 and the RAAS?a potential role for angiotensin II? Extract
  • GET 2020. Facts and reflections on COVID-19 and anti-hypertensives drugs Extract
  • GET ä. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Extract
  • GET 2020. Renin-Angiotensin-System (RAS) und COVID-19 - Zur Verordnung von RAS-Blockern Extract
  • GET 2020. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients Extract
  • GET ä. Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence Extract
  • GET ä. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19 Extract
  • GET ä. Might renin?angiotensin system blockers play a role in the COVID-19 pandemic? Extract
  • GET ä. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension Extract
  • GET ä. Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection Extract
  • GET ä. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension Extract
  • GET 2020. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Extract
  • GET 2020. Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non?COVID-19 Sepsis but Carries a Moderately Increased Risk of Death Extract
  • GET 2020. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB Extract
  • GET ä. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors?lessons from available evidence and insights into COVID-19 Extract
  • GET ä. Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System Extract
  • GET 2020. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? Extract
  • GET ä. More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19 Extract
  • GET ä. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 Extract
  • GET 2020. Angiotensin receptor blockers and COVID-19 Extract
  • GET ä. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic Extract
  • GET ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much? Extract
  • GET 2020. COVID-19 and the Renin-Angiotensin System Extract
  • GET ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 Extract
  • GET ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade Extract
  • GET ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade? Extract
  • GET ä. Controversy regarding ACE inhibitors / ARBs in Covid-19 Extract
  • GET 2020. Drugs and the renin-angiotensin system in covid-19 Extract
  • GET 2020. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations Extract
  • GET 2020. ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection? Extract
  • GET 2020. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 Extract
  • GET 2020. COVID-19 infections are also affected by human ACE1 D/I polymorphism Extract
  • GET 2020. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19 Extract
  • GET 2020. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence Extract
  • GET ä. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics Extract
  • GET 2020. RAAS blockers in hypertension posing a higher risk towards the COVID-19 Extract
  • GET 2020. EMA advice on renin-angiotensin system medicines during covid-19 pandemic Extract
  • GET 2020. (ang.)COVID-19 transmission through host cell directed network of GPCR Extract
  • GET 2020. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19 Extract
  • GET 2020. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections Extract
  • GET 2020. Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers Extract
  • GET 2020. ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2 Extract
  • GET ä. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox Extract
  • GET 2020. The ACE-2 in COVID-19: Foe or Friend? Extract
  • GET 2020. Renin-angiotensin system (RAS) blockers and the COVID-19 pandemic: at present there is no evidence to abandon RAS blockers Extract
  • GET 2020. ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective Extract
  • GET 2020. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study Extract
GET ä. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2 Extract
  • GET 2020. Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad? Extract
  • GET 2020. Response to four comments on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?? Extract
  • GET 2020. COVID-19, hypertension and angiotensin receptor-blocking drugs Extract
  • GET 2020. Comment on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?? Extract
  • GET 2020. Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder Extract
  • GET 2020. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? Extract
  • GET 2020. ACE2 and prognosis of COVID-19 Insights from Bartter s and Gitelman s syndromes patients Extract
  • GET 2020. What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients? Extract
  • GET 2020. Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19" Extract
  • GET 2020. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 Extract
  • GET 2020. Comment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19" Extract
  • GET ä. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) Extract
  • GET ä. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 Extract
  • GET ä. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China Extract
  • GET 2020. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers Extract
GET 2020. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 Extract
  • GET ä. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 Extract
  • GET ä. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19 Extract
  • GET ä. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Extract
  • GET ä. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease Extract
  • GET 2020. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia Extract
  • GET 2020. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19 Extract
  • GET 2020. ACE2 in the context of 2019-nCoV infection: friend or foe? Extract
GET 2020. EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic Extract
  • GET 2020. ACEI inhibitors and ARBs do not increase severity of COVID-19 Extract
  • GET ä. Status of SARS-CoV-2 infection in patients on renal replacement therapy Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)? Extract
  • GET ä. A potential protective role of losartan against coronavirus-induced lung damage Extract
  • GET 2020. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome Extract
  • GET ä. Bloqueantes del sistema renina-angiotensina e infeccion por COVID-19 Extract
GET ä. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels Extract
  • GET 2020. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic Extract
  • GET 2020. An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations Extract
  • GET 2020. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 Extract
  • GET ä. Supresion de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica Extract
  • GET ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality Extract
GET 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Extract
  • GET ä. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19 Extract
GET 2020. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2 Extract
GET ä. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury Extract
  • GET ä. Hypertension and COVID-19 Extract
  • GET 2020. The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection Extract
  • GET ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19? Extract
GET ä. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications Extract
  • GET ä. Renin-angiotensin system at the heart of COVID-19 pandemic Extract
  • GET 2020. Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19 Extract
  • GET ä. What is the Role of Angiotensin Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive, Diabetic Patients? Extract
  • GET ä. Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications Extract
GET 2020. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2 Extract
  • GET 2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections Extract
GET ä. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection Extract
  • GET 2020. COVID-19 and RAS: Unravelling an Unclear Relationship Extract

  • GET 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Extract
  • GET 2020. Angiotensin converting enzyme 2 (ACE2) and COVID-19: using antihypertensive medications, pharmacogenetic considerations. Extract
  • GET 2020. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Extract
  • GET 2020. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension? Extract
  • GET 2020. COVID-19, Renin-angiotensin System and Hematopoiesis. Extract
  • GET 2020. Severity of COVID-19: The importance of being hypertensive. Extract
  • GET 2020. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure". Extract
  • GET 2020. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure. Extract
  • GET 2020. Les bloqueurs du systeme renine-angiotensine-aldosterone en temps de pandemie Covid-19 : amis ou ennemis ? Extract
  • GET 2020. ACE-2 och coronavirus - en fraga om balans och dynamik? Extract
  • GET 2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. Extract
  • GET 2020. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication. Extract
  • GET 2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19. Extract
  • GET 2020. Exercise as medicine for COVID-19: An ACE in the hole? Extract
  • GET 2020. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2. Extract
  • GET 2020. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Extract
  • GET 2020. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues. Extract
  • GET 2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment. Extract
  • GET 2020. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply. Extract
  • GET 2020. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug. Extract
  • GET 2020. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells. Extract
  • GET 2020. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection. Extract
  • GET 2020. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic. Extract
  • GET 2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge